Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houedé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L.

J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13.

PMID:
31194611
2.

Unilateral or bilateral irradiation in cervical lymph node metastases of unknown primary? A retrospective cohort study.

Pflumio C, Troussier I, Sun XS, Salleron J, Petit C, Caubet M, Beddok A, Calugaru V, Servagi-Vernat S, Castelli J, Miroir J, Krengli M, Giraud P, Romano E, Khalifa J, Doré M, Blanchard N, Coutte A, Dupin C, Sumodhee S, Pointreau Y, Patel S, Rehailia-Blanchard A, Catteau L, Bensadoun RJ, Tao Y, Roth V, Geoffrois L, Faivre JC, Thariat J.

Eur J Cancer. 2019 Apr;111:69-81. doi: 10.1016/j.ejca.2019.01.004. Epub 2019 Feb 28.

PMID:
30826659
3.

Accelerated BRAF mutation analysis using a fully automated PCR platform improves the management of patients with metastatic melanoma.

Serre D, Salleron J, Husson M, Leroux A, Gilson P, Merlin JL, Geoffrois L, Harlé A.

Oncotarget. 2018 Aug 14;9(63):32232-32237. doi: 10.18632/oncotarget.25957. eCollection 2018 Aug 14.

4.

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.

Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, Buffet J, Pointreau Y, Sire C, Tuchais C, Babin E, Coutte A, Rolland F, Kaminsky MC, Alfonsi M, Lapeyre M, Saliou M, Lafond C, Jadaud E, Gery B, Zawadi A, Tourani JM, Khoury C, Henry AR, Hasbini A, Guichard F, Borel C, Meert N, Guillet P, Calais MH, Garaud P, Bourhis J.

J Clin Oncol. 2018 Jul 17:JCO2017762591. doi: 10.1200/JCO.2017.76.2591. [Epub ahead of print]

PMID:
30016178
5.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B.

N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.

6.

[Advances in the management of cervical lymphadenopathies of unknown primary with intensity modulated radiotherapy: Doses and target volumes].

Troussier I, Klausner G, Blais E, Giraud P, Lahmi L, Pflumio C, Faivre JC, Geoffrois L, Babin E, Morinière S, Maingon P, Thariat J.

Cancer Radiother. 2018 Sep;22(5):438-446. doi: 10.1016/j.canrad.2017.10.008. Epub 2018 May 3. Review. French.

PMID:
29731331
7.

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ.

Ann Oncol. 2018 Nov 1;29(11):2269. doi: 10.1093/annonc/mdx807. No abstract available.

8.

[Advances in the management of cervical lymphadenopathies of unknown primary: advances in diagnostic imaging and surgical modalities and new international staging system].

Troussier I, Klausner G, Morinière S, Blais E, Jean-Christophe Faivre, Champion A, Geoffrois L, Pflumio C, Babin E, Maingon P, Thariat J.

Bull Cancer. 2018 Feb;105(2):181-192. doi: 10.1016/j.bulcan.2017.11.009. Epub 2017 Dec 21. Review. French.

PMID:
29275831
9.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

Loriot Y, Pagliaro L, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Laplanche A, Le Teuff G, Culine S, Fizazi K.

Eur J Cancer. 2017 Dec;87:140-146. doi: 10.1016/j.ejca.2017.09.029. Epub 2017 Nov 14.

PMID:
29149760
10.

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH.

Ann Oncol. 2017 Oct 1;28(10):2526-2532. doi: 10.1093/annonc/mdx344.

11.

Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.

Tao Y, Aupérin A, Graff P, Lapeyre M, Grégoire V, Maingon P, Geoffrois L, Verrelle P, Calais G, Gery B, Martin L, Alfonsi M, Deprez P, Bardet E, Pignon T, Rives M, Sire C, Bourhis J.

Oral Oncol. 2017 Aug;71:61-66. doi: 10.1016/j.oraloncology.2017.06.002. Epub 2017 Jun 9.

PMID:
28688693
12.

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ.

Ann Oncol. 2017 Jun 1;28(6):1339-1345. doi: 10.1093/annonc/mdx075. Erratum in: Ann Oncol. 2018 Nov 1;29(11):2269.

13.

Long-term update of the 24954 EORTC phase III trial on larynx preservation.

Henriques De Figueiredo B, Fortpied C, Menis J, Lefebvre JL, Barzan L, de Raucourt D, Geoffrois L, Giurgea L, Hupperets P, Leemans CR, Licitra L, Rolland F, Tesselaar M, Vermorken JB, Grégoire V; EORTC Head and Neck Cancer and Radiation Oncology Cooperative Groups.

Eur J Cancer. 2016 Sep;65:109-12. doi: 10.1016/j.ejca.2016.06.024. Epub 2016 Aug 2.

PMID:
27494036
14.

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.

Oudard S, Joly F, Geoffrois L, Laguerre B, Houede N, Barthelemy P, Gross-Goupil M, Vano Y, Lucidarme O, Bidault F, Kelkouli N, Slimane K, Escudier B.

Clin Genitourin Cancer. 2016 Dec;14(6):e595-e607. doi: 10.1016/j.clgc.2016.04.019. Epub 2016 May 2.

PMID:
27283478
15.

Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.

Oudard S, Geoffrois L, Guillot A, Chevreau C, Deville JL, Falkowski S, Boyle H, Baciuchka M, Gimel P, Laguerre B, Laramas M, Pfister C, Topart D, Rolland F, Legouffe E, Denechere G, Amela EY, Abadie-Lacourtoisie S, Gross-Goupil M.

Eur J Cancer. 2016 Jul;62:28-35. doi: 10.1016/j.ejca.2016.04.003. Epub 2016 May 15.

PMID:
27192659
16.

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S.

Eur J Cancer. 2016 Feb;54:69-74. doi: 10.1016/j.ejca.2015.11.017. Epub 2015 Dec 25.

PMID:
26724422
17.

Sunitinib en rechallenge dans le cancer du rein métastatique-Résultats de l'étude RESUME.

Gimel P, Gross-Goupil M, Geoffrois L, Guillot A, Chevreau C, Deville J, Falkowski S, Boyle H, Baciuchka M, Laguerre B, Laramas M, Pfister C, Topart D, Rolland F, Legouffe E, Amela Y, Abadie S, Mahi N, Oudard S.

Prog Urol. 2014 Nov;24(13):821. doi: 10.1016/j.purol.2014.08.084. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461610
18.

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology.

Lancet Oncol. 2015 Jan;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11.

PMID:
25498218
19.

[Primary mediastinal germs cells tumors: a twenty years experience in a comprehensive cancer center].

Joly C, Deblock M, Desandes E, Geoffrois L.

Bull Cancer. 2014 Dec;101(12):1067-73. doi: 10.1684/bdc.2014.2047. French.

PMID:
25468207
20.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S.

Lancet Oncol. 2014 Dec;15(13):1442-1450. doi: 10.1016/S1470-2045(14)70490-5. Epub 2014 Nov 13.

21.

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.

Selle F, Wittnebel S, Biron P, Gravis G, Roubaud G, Bui BN, Delva R, Bay JO, Fléchon A, Geoffrois L, Caty A, Soares DG, de Revel T, Fizazi K, Gligorov J, Micléa JM, Dubot C, Provent S, Temby I, Gaulet M, Horn E, Brindel I, Lotz JP.

Ann Oncol. 2014 Sep;25(9):1775-82. doi: 10.1093/annonc/mdu198. Epub 2014 Jun 3.

PMID:
24894084
22.

[Contribution of an emergency dermatology consultation in a French cancer centre].

Reigneau M, Granel-Brocard F, Geoffrois L, Poreaux C, Peiffert D, Cuny JF, Bursztejn AC, Waton J, Schmutz JL, Barbaud A.

Ann Dermatol Venereol. 2014 May;141(5):375-8. doi: 10.1016/j.annder.2014.03.002. Epub 2014 Apr 12. French. No abstract available.

PMID:
24835652
23.

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.

Fizazi K, Gravis G, Flechon A, Geoffrois L, Chevreau C, Laguerre B, Delva R, Eymard JC, Rolland F, Houede N, Laplanche A, Burcoveanu D, Culine S.

Ann Oncol. 2014 May;25(5):987-91. doi: 10.1093/annonc/mdu099. Epub 2014 Mar 4.

PMID:
24595454
24.

[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC].

Thariat J, Jegoux F, Pointreau Y, Fayette J, Boisselier P, Blanchard P, Alfonsi M, Aupérin A, Bardet E, Bensadoun RJ, Garaud P, Geoffrois L, Graff P, Guigay J, Janot F, Lapeyre M, Lefebvre JL, Martin L, Racadot S, Rolland F, Sire C, Tao Y, Tuchais C, Chibaudel B, Girard-Calais MH, Cornely A, Vintonenko N, Calais G, De Raucourt D, Lacau Saint-Guily J, Bourhis J.

Bull Cancer. 2013 Oct;100(10):983-97. doi: 10.1684/bdc.2013.1829. Review. French.

PMID:
24126183
25.

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

Fizazi K, Delva R, Caty A, Chevreau C, Kerbrat P, Rolland F, Priou F, Geoffrois L, Rixe O, Beuzeboc P, Malhaire JP, Culine S, Aubelle MS, Laplanche A.

Eur Urol. 2014 Feb;65(2):381-6. doi: 10.1016/j.eururo.2013.09.004. Epub 2013 Sep 13.

PMID:
24094847
26.

Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis?

Reigneau M, Granel-Brocard F, Geoffrois L, Bauman AS, Tréchot P, Barbaud A, Schmutz JL.

Eur J Dermatol. 2013 Jul-Aug;23(4):544-5. doi: 10.1684/ejd.2013.2108. No abstract available.

PMID:
24001519
27.

[Adverse cutaneous effects and quality of life in patients treated with mTOR inhibitors for renal carcinoma].

Voilliot-Trotot C, Granel-Brocard F, Geoffrois L, Tréchot P, Nguyen-Thi P, Schmutz JL, Barbaud A.

Ann Dermatol Venereol. 2013 May;140(5):353-62. doi: 10.1016/j.annder.2013.02.023. Epub 2013 Apr 6. French.

PMID:
23663707
28.

Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes.

Peyrade F, Cupissol D, Geoffrois L, Rolland F, Borel C, Ciais C, Faivre S, Guigay J.

Oral Oncol. 2013 Jun;49(6):482-91. doi: 10.1016/j.oraloncology.2013.01.005. Epub 2013 Feb 13. Review.

PMID:
23415727
29.

Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.

Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E.

J Clin Oncol. 2013 Mar 1;31(7):853-9. doi: 10.1200/JCO.2012.42.3988. Epub 2013 Jan 22. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702.

PMID:
23341517
30.

Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02).

Thariat J, Bensadoun RJ, Etienne-Grimaldi MC, Grall D, Penault-Llorca F, Dassonville O, Bertucci F, Cayre A, De Raucourt D, Geoffrois L, Finetti P, Giraud P, Racadot S, Morinière S, Sudaka A, Van Obberghen-Schilling E, Milano G.

Clin Cancer Res. 2012 Sep 15;18(18):5123-33. Epub 2012 Aug 1.

31.

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.

Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A.

Lancet Oncol. 2012 Feb;13(2):145-53. doi: 10.1016/S1470-2045(11)70346-1. Epub 2012 Jan 18.

PMID:
22261362
32.

Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).

Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, Bompas E, Moxhon A, Mignion L, Guigay J, Knoops L, Hamoir M, Machiels JP.

Ann Oncol. 2012 Aug;23(8):2153-61. doi: 10.1093/annonc/mdr574. Epub 2012 Jan 10.

PMID:
22234739
33.

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B.

J Clin Oncol. 2012 Feb 10;30(5):482-7. doi: 10.1200/JCO.2011.37.2516. Epub 2012 Jan 9.

PMID:
22231040
34.

Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture.

Thariat J, Etienne-Grimaldi MC, Grall D, Bensadoun RJ, Cayre A, Penault-Llorca F, Veracini L, Francoual M, Formento JL, Dassonville O, De Raucourt D, Geoffrois L, Giraud P, Racadot S, Morinière S, Milano G, Van Obberghen-Schilling E.

Clin Cancer Res. 2012 Mar 1;18(5):1313-22. doi: 10.1158/1078-0432.CCR-11-2339. Epub 2012 Jan 6.

35.

[Evaluation of information about prophylactic treatment and management of hand-foot reactions caused by antiangiogenic therapies].

Guyot-Caquelin P, Geoffrois L, Barbaud A, Trechot P, Schmutz JL, Granel-Brocard F.

Ann Dermatol Venereol. 2011 Aug-Sep;138(8-9):565-71. doi: 10.1016/j.annder.2011.05.007. Epub 2011 Jun 23. French.

PMID:
21893229
36.

Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial.

Bourhis J, Lapeyre M, Tortochaux J, Lusinchi A, Etessami A, Ducourtieux M, Geoffrois L, Domenge C, Verrelle P, Wibault P, Janot F, Temam S, Blanchard P, Tao YG, Auperin A.

Radiother Oncol. 2011 Jul;100(1):56-61. doi: 10.1016/j.radonc.2011.07.006. Epub 2011 Aug 8.

PMID:
21831465
37.

[Metastatic paraganglioma. Answer to May e-quid].

Oldrini G, Geoffrois L, Olivier P, Henrot P, Blum A.

J Radiol. 2011 Jul-Aug;92(7-8):739-43. doi: 10.1016/j.jradio.2011.03.008. French. No abstract available.

PMID:
21819919
38.

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B, Escudier B.

Lancet Oncol. 2011 Jul;12(7):673-80. doi: 10.1016/S1470-2045(11)70124-3. Epub 2011 Jun 12.

PMID:
21664867
39.

Management of patients with head and neck tumours presenting at diagnosis with a synchronous second cancer at another anatomic site.

Graff P, Schipman B, Desandes E, Mecellem H, Toussaint B, Cortese S, Marchal F, Kaminsky MC, Geoffrois L, Peiffert D.

Clin Oncol (R Coll Radiol). 2011 Apr;23(3):174-81. doi: 10.1016/j.clon.2010.10.008. Epub 2010 Dec 3.

PMID:
21130631
40.

Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).

Lagrange JL, Bascoul-Mollevi C, Geoffrois L, Beckendorf V, Ferrero JM, Joly F, Allouache N, Bachaud JM, Chevreau C, Kramar A, Chauvet B; Study Group on Genito-Urinary Tumors.

Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):172-8. doi: 10.1016/j.ijrobp.2009.10.038. Epub 2010 Apr 10.

PMID:
20385453
41.

CT assessment of woodworkers' nasal adenocarcinomas confirms the origin in the olfactory cleft.

Georgel T, Jankowski R, Henrot P, Baumann C, Kacha S, Grignon B, Toussaint B, Graff P, Kaminsky MC, Geoffrois L, Vignaud JM.

AJNR Am J Neuroradiol. 2009 Aug;30(7):1440-4. doi: 10.3174/ajnr.A1648. Epub 2009 Jun 18.

42.

Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.

Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB; EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group.

J Natl Cancer Inst. 2009 Feb 4;101(3):142-52. doi: 10.1093/jnci/djn460. Epub 2009 Jan 27.

43.

[Sentinel lymph node biopsy for lymphophilic conjunctival and eyelid tumors: report of 8 cases].

Maalouf T, George JL, Geoffrois L, Olivier P, Dolivet G.

Rev Laryngol Otol Rhinol (Bord). 2009;130(4-5):231-4. French.

PMID:
20597403
44.

A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.

Theodore C, Chevreau C, Yataqhene Y, Fizazi K, Delord JP, Lotz JP, Geoffrois L, Kerbrat P, Bui V, Flechon A.

Ann Oncol. 2008 Aug;19(8):1465-9. doi: 10.1093/annonc/mdn122. Epub 2008 Apr 2.

PMID:
18385203
45.

Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.

Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP; Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.

J Clin Oncol. 2008 Jan 20;26(3):421-7. doi: 10.1200/JCO.2007.13.8461.

PMID:
18202419
46.

Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.

Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, Devaux Y, Lancry L, Chvetzoff G, Bachelot T, Chelghoum M, Biron P.

Support Care Cancer. 2008 Sep;16(9):1017-23. doi: 10.1007/s00520-007-0383-z. Epub 2008 Jan 15.

PMID:
18197434
47.

Endoscopic surgery reveals that woodworkers' adenocarcinomas originate in the olfactory cleft.

Jankowski R, Georgel T, Vignaud JM, Hemmaoui B, Toussaint B, Graff P, Geoffrois L, Henrot P, Kaminsky MC.

Rhinology. 2007 Dec;45(4):308-14.

PMID:
18085026
48.

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).

Culine S, Kerbrat P, Kramar A, Théodore C, Chevreau C, Geoffrois L, Bui NB, Pény J, Caty A, Delva R, Biron P, Fizazi K, Bouzy J, Droz JP; Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP).

Ann Oncol. 2007 May;18(5):917-24. Epub 2007 Mar 9.

PMID:
17351252
49.

[Myelotoxicity due to chemotherapy in oncology practice].

Geoffrois L.

Rev Prat. 2006 Nov 30;56(18):2009-14. Review. French.

PMID:
17274503
50.

Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers.

Fléchon A, Fizazi K, Gourgou-Bourgade S, Théodore C, Beuzeboc P, Geoffrois L, Mottet N, Chevreau C, Culine S.

Anticancer Drugs. 2006 Jul;17(6):705-8.

PMID:
16917216

Supplemental Content

Loading ...
Support Center